Jun. 29 at 7:49 PM
$CADL Anybody consider the implication of going alone vs a buyout? I know it comes with many more expenses and risks but if CAN-2409 and CAN-3110 have even half of the optimistic numbers being thrown around, I am not exactly sure why anyone would really want to sell a known commodity ( full pun intended) vs deploying funds into unknown waters
It would take some time but Prostate market would easily pay to explore the other indications.
Earnings per share calc:
$5B in earnings
75% expenses (fixed, variable and trials)
$1.25B for payout or share buy back (look at
$EXEL )
100M Shares
=
$12.50 / share
Seems like a pretty good rate of return on shares I bought for
$6.25. Even if share price is at
$100 that is better than most places in the market.
